Shares shifted as Kraken Robotics clawed back losses on Monday, trading up 4.3% to €5.05 after shedding roughly 6% in the days following its May 28 earnings report. Investors initially punished the underwater-technology firm for a quarterly net loss, but the recovery signals that the market is re-engaging with the bigger picture: a company betting that a massive acquisition and a back-loaded revenue year will turn red ink into serious profitability.
Revenue Surged, but the Bottom Line Spooked Investors
Q1 2026 revenue hit C$21.7 million, up 35% year-over-year , yet the figure missed the C$25.5 million analyst consensus . Worse, the company swung to a net loss of C$3.3 million — compared to a small profit a year earlier . Higher administrative costs from headcount expansion squeezed the adjusted EBITDA margin from 17% to 14% . That margin contraction, combined with the revenue miss, triggered the initial selloff — a classic case of high-growth expectations meeting messy quarterly execution.
A Monster Second Half Must Materialize Management is standing by its standalone 2026 forecast: revenue of C$165 million to C$175 million and adjusted EBITDA (earnings before interest, taxes, depreciation, and amortization) of C$40 million to C$50 million . Hitting the midpoint implies a full-year EBITDA margin above 26% — nearly double the Q1 figure . That means roughly C$143–153 million in revenue must flow through the final three quarters, a steep back-loaded ramp. CEO Greg Reid called Q1 "in-line with expectations," citing the seasonal nature of the offshore business .
The Order Book Provides Cover — For Now
Product orders in 2026 total C$97 million for Kraken, while Covelya has booked C$165 million — a combined pipeline of roughly C$262 million . That backlog gives credibility to the aggressive guidance, but it doesn't guarantee margins will recover.
The C$615 Million Covelya Deal Is the Real Swing Factor
Kraken is acquiring Covelya Group for C$615 million — C$480 million in cash, C$135 million in stock . The combined entity posted C$365 million in 2025 revenue at a 24% EBITDA margin . The deal remains on track to close near the end of Q2 2026 . But operating margins compressed from 15.1% to 8.4% last year during capacity expansion, and one customer accounts for 45% of 2025 sales — concentration risk that gets amplified, not diluted, by a larger balance sheet.
The rebound reflects conviction that the order pipeline and Covelya integration will deliver. The risk: shareholders are essentially buying a promise that Q2 through Q4 will look nothing like Q1.